Severity Assessment and IL-5 Evaluation after Immunotherapy in Atopic Dermatitis Mice

Sylvia Anggraeni, Dinar Chieko Triesayuningtyas, Hamidah Luthfidyaningrum, Made Putri Hendaria, Yuri Widia, Anang Endaryanto, Cita Rosita Sigit Prakoeswa

Abstract


Background: The effectiveness of immunotherapy in atopic dermatitis (AD) has been debated for many years. Immunotherapy suppresses Th2 cytokines, such as IL-5, which play a crucial role in the pathogenesis of AD. This study assessed the effect of immunotherapy on severity and IL-5 expression in AD mice.

Methods: Male BALB/c mice were separated into three groups. The mice were sensitized with Dermatophagoides pteronyssinus allergen for seven days, except the mice in control group. The house dust mite (HDM) immunotherapy was injected subcutaneously every 3 days for 1.5 months with increasing doses (0.1, 1, 10, 100 μg in 100 μL PBS) every 4 injections. The mice in AD model and control group received placebo injections. Following immunotherapy, the mice were exposed to HDM allergen patch two times with 2 weeks interval in between. The mice were evaluated for severity score as the clinical marker and IL-5 expression with semiquantitative method as the histological marker.

Results: The evaluation of severity score from two independent researchers showed a substantial agreement (Cohen’s kappa 0.613, p <0.001). The severity score of the immunotherapy group was significantly lower than the AD model group, while both immunotherapy and AD model group had significantly higher score than control group. IL-5 expression in the immunotherapy group was lower than the AD model group and slightly higher than control group. The mean difference between groups was not significant.

Conclusion: The severity of skin lesion and IL-5 expression in AD mice receiving immunotherapy were lower than AD model group.

Keywords: Atopic dermatitis; BALB/c mice; House dust mites; IL-5, Skin severity score; Tropical disease  


Full Text:

PDF

References


Feldman SR, Cox LS, Strowd LC, Gerber RA, Faulkner S, et al. The challenge of managing atopic dermatitis in the United States. American Health & Drug Benefits, (2019); 12(2): 83.

Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma and Immunology, (2018); 121(3): 340–7.

Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, et al. The global, regional, and national burden of atopic dermatitis in 195 countries and territories: an ecological study from the Global Burden of Disease Study 2017. JAAD International, (2021); 2: 12–8.

Sihaloho K, Indramaya DM. Penelitian Retrospektif : Dermatitis Atopik pada Anak. Berkala Ilmu Kesehatan Kulit dan Kelamin, (2015); 27(3): 176–82.

Anggraeni S, Umborowati MA, Damayanti, Endaryanto A, Rosita Sigit Prakoeswa C. Correlation between Skin Prick Test and Specific IgE of Local Mites Allergen in Atopic Dermatitis Patients: an Indonesian Study. Chiang Mai University Journal of Natural Sciences, (2022); 21(4): e2022053.

Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, et al. Allergen Immunotherapy in Children User’s Guide. Pediatric Allergy and Immunology, (2020); 31(Suppl.25): 1–101.

Cho YT, Chu CY. Advances in systemic treatment for adults with moderate-to-severe atopic dermatitis. Dermatologica Sinica, (2019); 37(1): 3.

Yang G, Seok JK, Kang HC, Cho YY, Lee HS, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. International Journal of Molecular Sciences, (2020); 21(8).

Herwanto N, Hutomo M. Retrospective Study: Management of Atopic Dermatitis. Berkala Ilmu Kesehatan Kulit dan Kelamin, (2016); 28(1): 45–54.

Putera AM, Hikmah Z, Endaryanto A, Irwanto, Maramis MM. The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial. Heliyon, (2021); 7(3).

Caminiti L, Panasiti I, Landi M, de Filippo M, Olcese R, et al. Allergen immunotherapy in atopic dermatitis: Light and shadow in children. Pediatric Allergy and Immunology, (2020); 31(Suppl.26): 46–8.

Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy, Asthma & Immunology Research, (2015); 7(3): 221–9.

Nowak M, Madej JA, Dzięgiel P. Intensity of COX2 Expression in Cells of Soft Tissue Fibrosarcomas in Dogs as Related to Grade of Tumour Malignancy. Bulletin of the Veterinary Institute in Pulawy, (2007); 51: 275–9.

Beck LA, Cork MJ, Amagai M, de Benedetto A, Kabashima K, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innovations, (2022); 2(5): 100131.

Murphy K, Weaver C, Janeway C. Janeway’s immunobiology 9th edition. 2017; New York: Garland science.

Hassoun D, Malard O, Barbarot S, Magnan A, Colas L. Type 2 immunity-driven diseases: Towards a multidisciplinary approach. Clinical and Experimental Allergy, (2021); 51(12): 1538–52.

Bumbacea R, Corcea S, Ali S, Dinica L, Fanfaret I, et al. Mite allergy and atopic dermatitis: Is there a clear link? (Review). Experimental and Therapeutic Medicine, (2020); 20: 3554–60.

Adji A, Niode NJ, Memah V v., Posangi J, Wahongan GJP, et al. Designing an epitope vaccine against Dermatophagoides pteronyssinus: An in silico study. Acta Tropica, (2021); 222.

Anggraeni S, Damayanti D, Umborowati MA, Riswanto CD, Rhatomy S, et al. Efficacy and safety of specific immunotherapy with aeroallergens in the management of atopic dermatitis. International Journal of Health Sciences, (2022); 6(S9): 2444–61.

Jutel M, Solarewicz-Madejek K, Węgrzyn A. Allergen-specific immunotherapy in atopic dermatitis. Postępy Dermatologii Alergologii XXVII, (2011); 5: 389–95.

Shin JU, Kim SH, Noh JY, Kim JH, Kim HR, et al. Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model. Allergy, (2018); 73(9): 1801–11.

Bencze J, Szarka M, Kóti B, Seo W, Hortobágyi TG, et al. Comparison of semi-quantitative scoring and artificial intelligence aided digital image analysis of chromogenic immunohistochemistry. Biomolecules, (2022); 12(1).

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Diagnostic Pathology, (2014); 9: 221.

Shershakova N, Bashkatova E, Babakhin A, Andreev S, Nikonova A, et al. Allergen-Specific Immunotherapy with Monomeric Allergoid in a Mouse Model of Atopic Dermatitis. PLoS One, (2015); 10(8): e0135070.




DOI: http://dx.doi.org/10.62940/als.v11i2.1710

Refbacks

  • There are currently no refbacks.